TNGX SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

NEWForm 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 9, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 11, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 13, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 5, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWTango Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Clinical Progress for Vopimetostat and TNG456

Nov 9, 2026

8-K

Tango Therapeutics Announces Promising Phase 1/2 Results for Vopimetostat Combinations in Pancreatic and Lung Cancer and Outlines Phase 3 Plans

Oct 23, 2026

8-K

Tango Therapeutics Files New Prospectus Supplement for At-the-Market Offering Program

Aug 11, 2026

8-K

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights

Aug 11, 2026

8-K/A

Tango Therapeutics Announces Executive Chair Transition

Aug 7, 2026

8-K

Departure of Tango Therapeutics Executive Chair Dr. Barbara Weber

Aug 6, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

August 2026 ATM | Offering amount: $400,000,000 | Bank: Leerink Partners LLC

Aug 11, 2026

424B5

REGISTERED OFFERING

Jun 10, 2026

424B5

PENDING FIXED PRICE OFFERING | Offering amount: $500,000,000 | Bank: J.P. Morgan

Jun 8, 2026

424B5

REGISTERED OFFERING

Oct 24, 2025

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Aug 10, 2022

424B3

Form 424B3 - Prospectus [Rule 424(b)(3)]

Jun 10, 2022

Registrations

TYPE

HEADLINE

FILED AT

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Jun 9, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 5, 2026

S-3ASR

November 2025 SHELF | Offering amount: $100,000,000

Nov 21, 2025

S-3

SHARE RESALE REGISTRATION

Nov 21, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Oct 28, 2025

FWP

Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses

Oct 23, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 17, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 17, 2026

DEFR14A

Form DEFR14A - Revised definitive proxy soliciting materials

Apr 23, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 22, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 21, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 11, 2025

Ownerships

TYPE

HEADLINE

FILED AT

SCHEDULE 13G/A

FMR LLC (Filed by)

Nov 6, 2026

Crystal Adam (Reporting)

Nov 4, 2026

Newcomb Jessica (Reporting)

Nov 4, 2026

144

Form 144 - Report of proposed sale of securities

Nov 2, 2026

Crystal Adam (Reporting)

Oct 5, 2026

Newcomb Jessica (Reporting)

Sep 24, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Dec 11, 2025

CORRESP

Form CORRESP - Correspondence

Dec 8, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

May 22, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 20, 2025

CORRESP

Form CORRESP - Correspondence

May 19, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Sep 12, 2023

Tango Therapeutics, Inc. TNGX · SEC Filings